Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

ClinicalTrials.gov ID: NCT01297543

Public ClinicalTrials.gov record NCT01297543. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this study, the safety, tolerability and activity of CLT-008 administered after "standard of care" cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD), neutrophil and platelet recovery, hMPC persistence, infections and complications.

Study identification

NCT ID
NCT01297543
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Cellerant Therapeutics
Industry
Enrollment
45 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2011 (Type not available)
Primary completion
Nov 2014 (Actual)
Completion
Jan 2015 (Actual)
Last update posted
Jul 1, 2016

2011 – 2015

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Moores UCSD Cancer Center La Jolla California 92037 —
University of California San Francisco Medical Center San Francisco California 94143 —
Stanford Hospital and Clinics Stanford California 94305 —
Loyola University Medical Center, Cardinal Bernardin Cancer Center Maywood Illinois 60153 —
Indiana Blood and Marrow Transplantation, LLC Beech Grove Indiana 46107 —
University of Massachusetts Memorial Medical Center Worcester Massachusetts 01655 —
University of Minnesota Minneapolis Minnesota 55455 —
Cleveland Clinic Cleveland Ohio 44195 —
The Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224 —
The University of Texas MD Anderson Cancer Center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01297543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 1, 2016 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01297543 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →